ST2 and galectin-3 as novel biomarkers for the prediction of future cardiovascular disease risk in preeclampsia

Basit Öğe Kaydı
dc.contributor.authorAtakul, Nil
dc.contributor.authorAtamer, Yildiz
dc.contributor.authorSelek, Sahabettin
dc.contributor.authorKilic, Berna
dc.contributor.authorKoktasoglu, Fatmanur
dc.date.accessioned2024-03-13T10:35:21Z
dc.date.available2024-03-13T10:35:21Z
dc.date.issued2022
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate known cardiovascular disease (CVD) risk biomarkers galectin-3 (Gal-3) and human stromelysin-2 (ST2) levels in preeclampsia (PE) and normotensive pregnancies. A case-control study was conducted in a teaching and research hospital. We performed data analysis involving 45 pregnant women with PE and gestational week (GW) matched 35 normotensive pregnant women. The Gal-3 and ST2 levels were determined by using ELISA kit. Gal-3 values did not differ statistically between PE and control groups (535.1 ng/mL vs. 615.2 ng/mL) (p> .05). ST2 value in the PE group was statistically significantly lower than the control group (33.3 pg/mL vs. PE, 54.5 pg/mL, p < .05). >34 GW patients (late-onset PE) had statistically significantly lower Gal-3 values than the <= 34 GW patients (early-onset PE) (507.1 ng/mL vs. 769.6 ng/mL, p < .05). Late-onset PE patients had significantly lower ST2 values than early-onset patients (26.4 pg/mL vs. 57.9 pg/mL, p < .05). We assume that low Gal-3 values in early-onset PE show a higher risk of cardiac fibrosis although both early and late-onset PE patients had an increased CVD risk later in life. We found the superiority of ST2 levels to Gal-3 levels in PE pregnancies for CVD risk assessment.Impact Statement What is already known about this subject? Preeclampsia (PE) in pregnancy is a known risk factor for future cardiovascular disease (CVD) and is also associated with increased mortality from ischaemic heart disease later in life. Studies that investigate patients with a higher risk for CVD in PE pregnancies are lacking. What do the results of this study add? We found different levels of two novel cardiac markers with PE and normotensive pregnancies, and also with early and late-onset PE pregnancies. What are the implications of these findings for clinical practice and/or further research? Different adaptive responses from patients during PE pregnancies via altered levels of cardiac markers could help clinicians to identify women with a higher risk of CVD.en_US
dc.identifier.doi10.1080/01443615.2021.1991293
dc.identifier.endpage1029en_US
dc.identifier.issn0144-3615
dc.identifier.issn1364-6893
dc.identifier.issue5en_US
dc.identifier.pmid34930081en_US
dc.identifier.scopus2-s2.0-85121703010en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1023en_US
dc.identifier.urihttps://doi.org/10.1080/01443615.2021.1991293
dc.identifier.urihttps://hdl.handle.net/20.500.12662/4377
dc.identifier.volume42en_US
dc.identifier.wosWOS:000732578900001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofJournal Of Obstetrics And Gynaecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPreeclampsiaen_US
dc.subjectgalectin-3en_US
dc.subjecthuman stromelysin-2en_US
dc.subjectcardiovascular disease risken_US
dc.titleST2 and galectin-3 as novel biomarkers for the prediction of future cardiovascular disease risk in preeclampsiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu